Abstract

Introduction

Both Food and Drugs Administration and European Medicine Agency (EMA) approve the use of a triphasic combined oral contraceptive (COC) containing ethinyl-oestradiol (EE) and norgestimate (NGM) for acne vulgaris treatment in women requiring an effective contraception. COCs can target sebum production and may also play a role in decreasing follicular hyperkeratinisation.

Results

Specific advantages of the use of an anti-androgenic progestin such as NGM in this condition are presented in this review, including the lowest venous thrombosis risk in the COCs scenario, as established by the EMA, associated with a very satisfactory cycle control. The results of aggregate analysis of published data (n = 163 vs. n = 161 treated subjects) demonstrate a significant effect in comparison with the placebo of a greater than 50% reduction, in terms of inflammatory lesions (from 19.0 to 8.2), comedones (from 35.2 to 17.7) and total lesions (from 54.3 to 25.9) count.

Conclusions

The choice of a triphasic combination of EE/NGM seems a referenced, highly effective, easy-to-use and safe therapeutic approach for acne vulgaris, alone or in combination with different targeted drugs.

中文翻译：

---

含诺孕酯的复方口服避孕药治疗寻常痤疮的作用：综述

摘要

介绍

美国食品药品监督管理局和欧洲药品管理局 (EMA) 批准使用含有乙炔雌二醇 (EE) 和诺孕酯 (NGM) 的三相复方口服避孕药 (COC) 治疗需要有效避孕的女性寻常痤疮。COC 可以针对皮脂产生，也可能在减少毛囊角化过度方面发挥作用。

结果

本综述介绍了在这种情况下使用 NGM 等抗雄激素孕激素的具体优点，包括 EMA 确定的 COC 方案中静脉血栓形成风险最低，与非常令人满意的周期控制相关。已发表数据的汇总分析结果（n  = 163 vs. n  = 161 治疗受试者）表明，与安慰剂相比，在炎症病变（从 19.0 至 8.2）、粉刺方面，效果显着，减少了 50% 以上（从 35.2 到 17.7）和总病变（从 54.3 到 25.9）计数。

结论

选择EE/NGM三相组合单独或与不同靶向药物联合治疗寻常痤疮似乎是一种可参考的、高效、易于使用且安全的治疗方法。